Regeneron Pharmaceuticals, Inc. REGN announced disappointing top-line data from an ongoing phase II CAPELLA study, evaluating Eylea (aflibercept) in combination with rinucumab (an anti-PDGFR-beta ...

Shares of Regeneron Pharmaceuticals, Inc. (NASD:REGN) climbed 11.78% to $300.32 per share on Jan 14 following the rosy fourth quarter 2013 outlook provided by the company on its eye drug Eylea. As ...

On a standalone basis, Eylea sales were $1.19 billion in the United States in the fourth quarter of 2024. Eylead HD’s net product sales were $305 million in the fourth quarter of 2024 in the ...

Despite Eylea reaching the market first, Roche has eroded a stake of Bayer’s market share with its bispecific antibody Vabysmo. Similar to Eylea, Vabysmo is approved for a range of retinal ...

Kodiak Sciences Inc's eye drug failed to match Regeneron Pharmaceuticals' Eylea in improving the vision of patients in a study, sending its shares tumbling nearly 80% on Wednesday.

With U.S. sales of $304 million during the second quarter, Regeneron’s high-dose version of Eylea came up just short of analyst projections. | The launch of Regeneron's Eylea HD has helped the ...

Eylea will run $1,850 per dose, Bloomberg reports, compared with $2,000 for Lucentis, and $16,000 for a full year, compared with $24,000 for the Roche drug.

To begin, Eylea and Dupixent should provide a bedrock of $8–10 billion in revenue for years to come. Second, Regeneron's oncology pursuits are bearing fruit, as evidenced by Libtayo's impressive ...

A higher dose of Regeneron and Bayer's Eylea given every three or four months has shown efficacy in a pair of clinical trials, in a big boost for the multibillion-dollar product.

Regeneron Pharmaceuticals Inc. said an extensive investigation into a rare and frightening side effect seen in clusters of patients getting its best-selling drug Eylea has been tied to syringes ...

The eye-drug pricing war just got tighter for Roche’s injection Lucentis: An NIH-funded study comparing Lucentis (ranibizumab) against its cancer drug Avastin (bevacizumab) as well as Regeneron’s ...